Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Avalyn Pharma Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT07194382
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
- Conditions
- Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Avalyn Pharma Inc.
- Target Recruit Count
- 340
- Registration Number
- NCT06951217
- Locations
- 🇦🇺
Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺Royal Prince Alfred Hospital, Camperdown, Australia
🇦🇺The Prince Charles Hospital (TPCH), Chermside, Australia
A Placebo-Controlled Study of Inhaled Pirfenidone in Progressive Pulmonary Fibrosis
- Conditions
- Progressive Pulmonary Fibrosis
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Avalyn Pharma Inc.
- Target Recruit Count
- 141
- Registration Number
- 2023-508429-29-00
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Pulmonary Associates, PA, Phoenix, Arizona, United States
🇺🇸University of Southern California, Los Angeles, California, United States
News
Avalyn Pharma Unveils AURA-IPF Phase 2 Trial Design for Inhaled Nintedanib at ERS Congress 2025
Avalyn Pharma will present the AURA-IPF Phase 2 clinical trial design for AP02, an inhaled formulation of nintedanib, at the European Respiratory Society International Congress 2025.